Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 36

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 36
---
 evaluate our executives’ performance are described below. For more information refer to the “Elements of Executive Compensation” of this proxy statement.

| Most Important Performance Measures                                                                                                                                                   |
| Increase revenue                                                                                                                                                                      |
| Expand our commercial business serving patients with hypercortisolism and continue to advance relacorilant as a potentially superior successor to Korlym                              |
| Advance promising candidates from our portfolio of selective cortisol modulators as potential treatments for patients with solid tumors, metabolic disorders and neurologic disorders |
| Discover and advance towards the clinic additional selective cortisol modulators and identify serious disorders for which they might fill an unmet medical need                       |

Pay versus Performance Comparative Disclosure

The following reflect the relationships between (i) CAP to our CEO, and the average of CAP to our non-CEO NEOs, to our cumulative total shareholder return and our cumulative total shareholder return (“TSR”) to our peer group (as defined above) TSR, (ii) CAP to our CEO, and the average of CAP to our non-CEO NEOs, to our revenues, and (iii) CAP to our CEO, and the average of CAP to our non-CEO NEOs, to our net income, in each case for the years 2020 through 2024.

<div align='center'>26

27

28</div>

### EQUITY COMPENSATION PLAN INFORMATION
The following table provides information as of December 31, 2024 with respect to the shares of our common stock that may be issued under our equity compensation plan, the 2024 Plan.

| Plan Category                                         |     | (a)                                                                                                    
 Number of Securities to be Issued upon Exercise of Outstanding Options and Vesting of Restricted Stock 
 (

# of shares)                                                                                          |            |     | (b)                                                    
 Weighted Average Exercise Price of Outstanding Options 
 ($/share)(1)                                           |       |     | (c)                                                                                                        
 Number of Securities                                                                                       
 Available for Future Issuance Under Equity Compensation Plan (Excluding Securities Reflected in Column(a)) 
 (

# of shares)                                                                                              |            |     |    |
|:------------------------------------------------------|:----|:-------------------------------------------------------------------------------------------------------|-----------:|:----|:-------------------------------------------------------|------:|:----|:-----------------------------------------------------------------------------------------------------------|-----------:|:----|---:|
| Equity compensation plan approved by stockholders     |     |                                                                                                        | 25,956,660 |     | $                                                      | 18.29 |     |                                                                                                            | 10,